Preoperative Prediction of Acute Kidney Injury After Cardiac Surgery (RFR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Although acute kidney injury (AKI) frequently complicates cardiac surgery, methods to determine AKI risk are lacking. Renal functional reserve (RFR), the capacity of the intact nephron mass to increase glomerular filtration rate (GFR), represents maximal filtration capacity. We hypothesized that preoperative RFR would predict postoperative AKI.
Condition or disease
Acute Kidney Injury
Other: No intervention
Acute kidney injury (AKI) is a frequent complication in patients undergoing cardiac surgery with an estimated prevalence of 36%. However, clinicians have limited tools to preoperatively identify patients at risk for AKI and/or progression to chronic kidney disease, particularly in patients with normal resting glomerular filtration rate (rGFR). Renal functional reserve (RFR) describes the capacity of the intact nephron mass to increase GFR from baseline in response to stimuli (e.g., protein load). We hypothesized that the presence or absence of RFR could separate patients at risk for developing AKI from patients with better-preserved renal function and a more favorable short- and long-term prognosis despite identical rGFR. The aim of this study is to examine whether preoperative assessment of RFR is able to predict risk for AKI after cardiac surgery.
The predictive value of RFR for AKI in patients undergoing elective cardiac surgery [ Time Frame: 1 day before cardiac surgery ]
Secondary Outcome Measures :
Whether the occurrence of AKI (as defined by Kidney Disease Improving Global Outcomes criteria) impacts RFR three months after surgery in patients without ongoing reduced function defined by resting GFR [ Time Frame: 3 months after cardiac surgery ]
Whether urinary [TIMP-2][IGFBP7] predicts loss of RFR [ Time Frame: 3 months after cardiac surgery ]
Biospecimen Retention: Samples With DNA
Collection of only residual material (blood, urine) for International Renal Research Institute
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients undergoing elective cardiac surgery
Subjects older than 18 years
Subjects undergoing elective cardiac surgery
Subjects who signed informed consent forms
Chronic kidney disease ≥ stage III
Diabetes mellitus type 1
Recent cardiac arrest
Liver failure or cirrhosis
Total parenteral nutrition
Hemoglobin <11 g/dl
History of malabsorption, chronic inflammatory bowel disease, short bowel, or pancreatic insufficiency
Transplant donor or recipient
Active autoimmune disease with renal involvement
Prostate hypertrophy with International Prostate Symptom Score ≥20
All patients included in the study were to be followed up until the scheduled end of the study. Data collection could be terminated prior to the scheduled time only under the following conditions:
A patient or his/her legal representative may refuse further participation in the study at any time (withdrawal of consent),
The investigator may withdraw a patient from the participation in the study at any time for the following reasons:
a severe protocol violation,
the development of incidents/near-incidents/other severe clinical complications related to the study protocol
Criteria related to the study
Subjects who could not stop taking angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers a minimum of 48 hours before the protein load.
Subjects who received non-steroidal anti-inflammatory drugs within the 48 hours before the protein load.
Subjects who received intravenous radiocontrast agents within the 72 hours before the protein load.